Enzon Pharmaceuticals, Inc.
$5.75+0.00%(+$0.00)
TickerSpark Score
58/100
90
Valuation
20
Profitability
10
Growth
72
Health
100
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENZN research report →
52-Week Range67% of range
Low $0.02
Current $5.75
High $8.55
Companywww.enzon.com
Enzon Pharmaceuticals, Inc. , together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron.
- CEO
- Richard L. Feinstein
- IPO
- 1984
- Employees
- 1
- HQ
- Cranford, NJ, US
Price Chart
-42.33% · this period
Valuation
- Market Cap
- $4.27M
- P/E
- -4.76
- P/S
- 0.05
- P/B
- 0.24
- EV/EBITDA
- -39.43
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 9.78%
- Op Margin
- -5.00%
- Net Margin
- -11.06%
- ROE
- -13.78%
- ROIC
- -1.18%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-3,409,000 · -538.17%
- EPS
- $-7.46 · -1013.43%
- Op Income
- $-1,356,000
- FCF YoY
- -368.27%
Performance & Tape
- 52W High
- $8.55
- 52W Low
- $0.02
- 50D MA
- $4.83
- 200D MA
- $1.26
- Beta
- -0.02
- Avg Volume
- 26.29K
Get TickerSpark's AI analysis on ENZN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 30, 26 | Pettit Craig | other | 0 |
| Jan 7, 25 | WILLS STEPHEN T | other | 0 |
| Jun 16, 23 | READ RANDOLPH C | buy | 84,550 |
| Jun 14, 23 | READ RANDOLPH C | buy | 15,000 |
| Jun 9, 22 | Firestone Jaffrey Adam | other | 0 |
| Aug 13, 21 | COUCHMAN JONATHAN | sell | 57,500 |
| Aug 13, 21 | COUCHMAN JONATHAN | sell | 50,000 |
| Nov 18, 20 | READ RANDOLPH C | buy | 50,000 |
| Nov 16, 20 | READ RANDOLPH C | buy | 50,450 |
| Nov 13, 20 | Bleznick Jordan | buy | 100,000 |
Our ENZN Coverage
We haven't published any research on ENZN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ENZN Report →Similar Companies
CLABF+0.00%
Core One Labs Inc.
$0.00
FNAM+0.00%
Evolutionary Genomics, Inc.
$0.00
SRNE+0.00%
Sorrento Therapeutics, Inc.
$0.00
TDSGF-38.00%
Telo Genomics Corp.
$0.03
SIGY+3.68%
Sigyn Therapeutics, Inc.
$0.04
DOSEF-29.97%
Doseology Sciences Inc.
$0.32
CTABF+0.00%
Canntab Therapeutics Limited
$0.00
HLYK-9.85%
HealthLynked Corp.
$1.86